AbbVie's Rinvoq Shows Durable Efficacy in Vitiligo Long-Term Data
ABBV sits 37% above its 52-week low of $190.75 on light trading volume (0.2× avg).
Summary
AbbVie presented long-term data supporting Rinvoq for vitiligo, reinforcing its efficacy and safety profile. Phase 3 studies show continued repigmentation with Rinvoq through week 76. This follows the European Commission's approval of Rinvoq for non-segmental vitiligo in July, making it the first systemic treatment for the condition. The new data could strengthen AbbVie's position in the dermatology market and support future label expansions. Rinvoq is already a key growth driver for AbbVie, with Q2 revenue up 10% year-over-year. Investors will watch for potential FDA approval and commercial uptake in the U.S.
At the time of this announcement, ABBV was trading at $260.38 on NYSE in the Life Sciences sector, with a market capitalization of approximately $460.1B. The 52-week trading range was $190.75 to $269.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.